Delta-MRD400

**Semantic type:** Finding

**Definition:** An indication of a 400-fold reduction in measurable residual disease (MRD) correlated to the expression of clonal B-cell receptors (BCR) and T-cell receptors (TCR) in peripheral blood cell samples from subjects following treatment of a lymphoid malignancy as determined by the proprietary next generation sequencing-based clonoSEQ assay.

**Synonyms:** - 400-fold Clonal BCR/TCR Reduction - 400-fold MRD Reduction - 400-fold Measurable Residual Disease Reduction - 400-fold Reduction in Clonal Lymphoid Markers - Delta MRD400